Potential use of serum insulin‐like growth factor 1 and E‐cadherin as biomarkers of colorectal cancer

E-cadherin Beyond Structure: A Signaling Hub in Colon Homeostasis and Disease

(2019) Amanda C. Daulagala et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target

(2019) Weina Yu et al.   Frontiers in Oncology

Expressions of IGF-1, ERK, GLUT4, IRS-1 in metabolic syndrome complicated with colorectal cancer and their associations with the clinical characteristics of CRC

(2018) Jianxia Hu et al.   Cancer Biomarkers

Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R/InsR inhibitors

(2018) Alison M Nagle et al.   CLINICAL CANCER RESEARCH

The mechanisms linking obesity to colon cancer: An overview

(2018) Aleksandra Tarasiuk et al.   Obesity Research & Clinical Practice

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development

(2018) Milica Stevanovic et al.   Biochemia Medica

Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults

(2017) Huijuan Zhu et al.   PLoS One

IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process

(2016) Vincent Le Coz et al.   Oncotarget

Insulin-like Growth Factor-1, IGF-binding Protein-3, C-peptide and Colorectal Cancer: a Case-control Study

(2015) Pankaj Joshi et al.   Asian Pacific Journal of Cancer Prevention

Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial–mesenchymal transition in non-small cell lung cancer

(2014) Fariz Nurwidya et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Reference Intervals for Insulin-like Growth Factor-1 (IGF-I) From Birth to Senescence: Results From a Multicenter Study Using a New Automated Chemiluminescence IGF-I Immunoassay Conforming to Recent International Recommendations

(2014) Martin Bidlingmaier et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Loss of E-Cadherin Expression Is Associated with a Poor Prognosis in Stage III Colorectal Cancer

(2014) Jung-A Yun et al.   ONCOLOGY

The Expression of LEP, LEPR, IGF1 and IL10 in Obesity and the Relationship with microRNAs

(2014) Renata Viesti A. Collares et al.   PLoS One

Levels of Soluble E-Cadherin in Breast, Gastric, and Colorectal Cancers

(2014) Ombretta Repetto et al.   Biomed Research International

Colorectal cancer

(2013) Hermann Brenner et al.   LANCET

Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer

(2013) Zhen-Jun Li   WORLD JOURNAL OF GASTROENTEROLOGY

Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma

(2012) ADAM ELZAGHEID et al.   APMIS

Clinical Significance of Serum Soluble E-cadherin in Colorectal Carcinoma

(2011) Yoshinaga Okugawa et al.   JOURNAL OF SURGICAL RESEARCH

IGF system in cancer

(2010) Jorge Chaves et al.   ANTI-CANCER DRUGS

Soluble E-cadherin as a serum biomarker candidate: Elevated levels in patients with late-stage colorectal carcinoma and FAP

(2010) Jakob V. Weiß et al.   INTERNATIONAL JOURNAL OF CANCER

Receiver Operating Characteristic Curve in Diagnostic Test Assessment

(2010) Jayawant N. Mandrekar   Journal of Thoracic Oncology

Growth hormone, the insulin-like growth factor axis, insulin and cancer risk

(2010) Peter E. Clayton et al.   Nature Reviews Endocrinology

Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies

(2009) Sabina Rinaldi et al.   INTERNATIONAL JOURNAL OF CANCER